Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products
Open Access
- 8 May 2003
- journal article
- fj express-summarie
- Published by Wiley in The FASEB Journal
- Vol. 17 (10), 1289-1291
- https://doi.org/10.1096/fj.02-0490fje
Abstract
Endothelial damage is believed to play a key role in the development of both micro- and macrovascular disease in diabetes, and advanced glycation end products (AGEs) may contribute importantly to thi...Keywords
This publication has 57 references indexed in Scilit:
- Scavenger Receptor Class B Type I-mediated Reverse Cholesterol Transport Is Inhibited by Advanced Glycation End ProductsJournal of Biological Chemistry, 2001
- Role of galectin-3 as a receptor for advanced glycosylation end productsKidney International, 2000
- Characterization of the Advanced Glycation End-Product Receptor Complex in Human Vascular Endothelial CellsBiochemical and Biophysical Research Communications, 1999
- AMP‐activated protein kinase phosphorylation of endothelial NO synthaseFEBS Letters, 1999
- Diabetes, advanced glycation endproducts and vascular diseaseVascular Medicine, 1998
- Urinary Albumin Excretion and History of Acute Myocardial Infarction in a Cross-Sectional Population Study of 2613 IndividualsEuropean Journal of Preventive Cardiology, 1997
- Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin‐producing ability of endothelial cells through interactions with their receptorsFEBS Letters, 1996
- N.epsilon.-(Carboxymethyl)lysine Is a Dominant Advanced Glycation End Product (AGE) Antigen in Tissue ProteinsBiochemistry, 1995
- Widespread tissue distribution, species distribution and changes in activity of Ca2+‐dependent and Ca2+‐independent nitric oxide synthasesFEBS Letters, 1991
- The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature, 1980